Clinical Trial Update: An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial evaluating lumateperone as adjunctive therapy for Major depressive disorder; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Caplyta (lumateperone)

Snippet

Sponsor: Intra-Cellular Therapies, Inc. | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2025-11-03